FindTrial
Sign In

Efficacy and safety of a 4 year pubertal therapy with growth hormone (Omnitrope) or growth hormone and an aromatase inhibitor (Letrozole) in boys with a short predicted height.

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519935-41-00
Acronym
BSGPE2
Enrollment
50
Registered
2025-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short predicted height

Brief summary

Adult height gain = Final height minus predicted adult height

Interventions

DRUGOmnitrope 10 mg/1.5 ml solution for injection in cartridge
DRUGLetrozole Fair-Med Healthcare 2.5 mg film coated tablets

Sponsors

Universitair Ziekenhuis Antwerpen
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Adult height gain = Final height minus predicted adult height—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026